Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease/Experiment 3

From BugSigDB


Reviewed Marked as Reviewed by Peace Sandy on 2024-2-24

Curated date: 2023/10/12

Curator: Chinelsy

Revision editor(s): Chinelsy, Peace Sandy

Subjects

Location of subjects
Malawi
Zimbabwe
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Sputum Expectoration,Sputum,sputum
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Azithromycin (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-,10q24.1-q25.1,aritromicina,Azenil,Azifast,Azigram,Azimakrol,azithromycine,azithromycinum,Azitromin,AZM,Hemomycin,InChIKey=MQTOSJVFKKJCRP-BICOPXKEBK,Zithromax,Zmax,Azithromycin,azithromycin
Group 0 name Corresponds to the control (unexposed) group for case-control studies
AZM at baseline - Azithromycin arm only
Group 1 name Corresponds to the case (exposed) group for case-control studies
AZM at 48 weeks - Azithromycin arm only
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Participants with HIV-associated Chronic Lung Disease (HCLD) who received azithromycin (AZM) at 48weeks
Group 0 sample size Number of subjects in the control (unexposed) group
173
Group 1 sample size Number of subjects in the case (exposed) group
154
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
NIL

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
centered log-ratio
Statistical test
ANCOM
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes
Confounders controlled for Confounding factors that have been accounted for by stratification or model adjustment
age, sex

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged

Signature 1

Reviewed Marked as Reviewed by Peace Sandy on 2024-2-24

Curated date: 2023/10/12

Curator: Chinelsy

Revision editor(s): Chinelsy, Peace Sandy

Source: Table S 8.

Description: Results of differential abundance testing of bacterial taxa from samples from the AZM arm at baseline and 48 72 weeks using 10 methods.

Abundance in Group 1: increased abundance in AZM at 48 weeks - Azithromycin arm only

NCBI Quality ControlLinks
Lautropia
Moraxella
Treponema
Oribacterium

Revision editor(s): Chinelsy, Peace Sandy